实体肿瘤免疫相关疗效评价标准的研究进展-中国肿瘤生物治疗杂志.PDFVIP

中国肿瘤生物治疗杂志 Chin J Cancer Biother, Jul. 2018, Vol. 25, No. 7 ·663 · DOI：：10.3872/j.issn.1007-385x.2018.07.001 ∙专家论坛∙ 实体肿瘤免疫相关疗效评价标准的研究进展 白日兰，崔久嵬（吉林大学 第一医院 肿瘤中心，吉林 长春 130021） [摘 要] 近几年，免疫检查点抑制剂疗法飞速发展并取得突破性进展，成为多种晚期肿瘤的首选疗法。但由于其激活抗肿瘤 免疫系统的独特作用模式，多种非常规缓解模式相继出现，如延迟反应和假性进展等，给传统疗效评价标准带来挑战，进而促使 人们不断探索应对免疫治疗特殊反应的评价指南。本文主要对实体肿瘤多种免疫治疗相关疗效评价标准的探索进程、研究进展 及各指南间异同进行系列阐述，并对其目前的挑战和未来发展趋势进行展望。 [关键词] 实体肿瘤；肿瘤免疫治疗；假性进展；疗效评价标准 [中图分类号] R730.5 [文献标识码] A [文章编号] 1007-385X （2018 ）07-0663-06 Advanced research of immune-related response evaluation criteria in solid tumors BAI Rilan, CUI Jiuwei （Cancer Center, the First Hospital of Jilin University, Changchun 130021, Jilin, China） [Abstract] In recent years, therapy of immune checkpoint inhibitors have developed rapidly and made breakthrough, becoming the first-line treatment for many types of advanced cancer. However, due to its particular mode in activating the anti-tumor immune system, a variety of unconventional response patterns have emerged, such as delayed response and pseudoprogression, which have challenged the traditional response evaluation criteria and encouraged people to continuously explore new criteria for evaluating the unconvention- al response patterns under immunotherapy. This article mainly reviews the process of exploration, advanced research,as well as similari- ties and differencesamongvarious immune-related efficacy evaluation criteria, and finally prospects the current challenges and future trends. [Key words] solid tumor; tumor immunotherapy; pseudoprogression; response evaluation criteria [Chin J Cancer Biother, 2018, 25(7): 663-668. DOI ：10.3872/j.issn. 1007-385X.2018.07.001] 崔久嵬教授、主任医师、博士生导师， 小变化为判定标准。近几年，随着人们对肿瘤免疫 现任吉林大学第一医院肿瘤中心肿瘤 学研究的逐步深入，肿瘤疫苗、特异性单克隆抗体及 科主任，兼任中国抗癌协会青